Compare ADMA Biologics Inc (ADMA) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs T-Mobile Us Inc — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while T-Mobile Us Inc trades at $182.74 (market cap $199.92B). The key difference: T-Mobile Us Inc is far larger — about 93.9× ADMA Biologics Inc's market cap, and T-Mobile Us Inc pays a 2.21% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | TMUS | |
|---|---|---|
Market Cap | $2.13B | $199.92B |
Sector | Health | Media |
52-Week High | $20.38 | $259.01 |
52-Week Low | $7.60 | $167.65 |
Enterprise Value | $2.20B | $317.61B |
Dividend Yield | — | 2.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
T-Mobile US (TMUS) trades at $184.73, up 4.06% on the day, with a bullish analyst consensus but bearish technical signals. The stock shows strong fundamentals with revenue growth to $88.31B in 2025 and a net income margin of 11.65%, though earnings have been mixed with a recent miss in Q4 2025. Recent news includes leadership changes and speculation about SpaceX's potential interest, while cash flow remains positive but projected to decline in 2026.
Outlook: TMUS offers growth potential with solid profitability and analyst targets near $256, but faces risks from competitive pressures and debt levels. Investment appeal hinges on execution amid sector volatility and macroeconomic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
